We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 2, 2026 – Stocks in this week’s article are Microsoft Corp. (MSFT - Free Report) , Harmony Biosciences Holdings, Inc. (HRMY - Free Report) , Universal Health Services, Inc. (UHS - Free Report) , Concentrix Corp. (CNXC - Free Report) and Global Payments Inc. (GPN - Free Report) .
4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street
The U.S. stock market remained subdued yesterday. While the Dow Jones Industrial Average gained 0.11% (+55.96 points) to 49,071.56, the broader market faced downside pressure. The S&P 500 slipped 0.13% to 6,969.01, while the tech-heavy Nasdaq Composite declined 0.72% to 23,685.12.
The technology sector set the tone for the session, with a sharp sell-off seen in Microsoft Corp. shares, after its earnings report reignited concerns about slower cloud growth. Some of this pressure was offset by strength in Meta, but overall sentiment remained cautious due to rising oil prices and geopolitical tensions. Amid this backdrop, value stocks present an appealing opportunity.
When evaluating value stocks, one of the most effective valuation metrics is the Price to Cash Flow (P/CF) ratio. This metric measures the market price of a stock relative to the cash flow the company generates on a per-share basis. A lower P/CF ratio indicates that the stock is trading at a better value, offering strong cash generation potential relative to its price. Here are four companies — Harmony Biosciences Holdings, Inc., Universal Health Services, Inc., Concentrix Corp. and Global Payments Inc. — that boast a low P/CF ratio.
Price to Cash Flow Reveals Financial Health
Questions may arise as to why we are considering the P/CF valuation metric when the most widely used metric is Price/Earnings (or P/E). Well, what makes P/CF stand out is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, reflecting a company's financial health.
Analysts caution that a company's earnings are subject to accounting estimates and management manipulation. However, cash flow is reliable. It is net cash flow that reveals how much money a company is actually generating and how effectively management is putting the same to use.
A positive cash flow indicates an increase in the company's liquid assets. This gives the company the means to settle debt, shell out for its expenses, reinvest in its business, endure downturns and finally pay back its shareholders. Then again, a negative cash flow implies a decline in the company's liquidity, which lowers its flexibility to support these moves.
What's the Best Value Investing Strategy?
An investment decision solely based on the P/CF metric may not fetch the desired results. To identify stocks that are trading at a discount, you should expand your search criteria and consider the price-to-book ratio, price-to-earnings ratio and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of A or B to your search criteria should lead to even better results, as these eliminate the chance of falling into a value trap.
Here are four of the nine value stocks that qualified the screening:
Harmony Biosciences, a pharmaceutical company, sports a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 7.2%, on average. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Harmony Biosciences' current financial-year sales and earnings per share (EPS) indicates growth of 21.4% and 25.9%, respectively, from the year-ago period. HRMY has a Value Score of A. Shares of HRMY have lost 4.9% in the past year.
Universal Health Services, which through its subsidiaries owns and operates acute care hospitals and outpatient and behavioral health care facilities, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 15.2%, on average.
The Zacks Consensus Estimate for Universal Health Services' current financial-year sales and EPS calls for growth of 9.7% and 31.3%, respectively, from the year-ago period. UHS has a Value Score of A. Shares of UHS have risen 6.1% in the past year.
Concentrix Corporation, a global technology and services leader providing customer experience solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 1%, on average.
The Zacks Consensus Estimate for Concentrix's current financial-year sales and EPS suggests growth of 2.9% and 4.8%, respectively, from the year-ago period. CNXC has a Value Score of A. Shares of CNXC have plunged 26.1% in the past year.
Global Payments, a leading worldwide provider of payment technology and software solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 1.9%, on average.
The Zacks Consensus Estimate for Global Payments' current financial-year sales and EPS implies growth of 1.8% and 5.8%, respectively, from the year-ago period. GPN has a Value Score of A. Shares of GPN have plunged 36.8% in the past year.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and backtest them first before taking the investment plunge.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments
For Immediate Release
Chicago, IL – February 2, 2026 – Stocks in this week’s article are Microsoft Corp. (MSFT - Free Report) , Harmony Biosciences Holdings, Inc. (HRMY - Free Report) , Universal Health Services, Inc. (UHS - Free Report) , Concentrix Corp. (CNXC - Free Report) and Global Payments Inc. (GPN - Free Report) .
4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street
The U.S. stock market remained subdued yesterday. While the Dow Jones Industrial Average gained 0.11% (+55.96 points) to 49,071.56, the broader market faced downside pressure. The S&P 500 slipped 0.13% to 6,969.01, while the tech-heavy Nasdaq Composite declined 0.72% to 23,685.12.
The technology sector set the tone for the session, with a sharp sell-off seen in Microsoft Corp. shares, after its earnings report reignited concerns about slower cloud growth. Some of this pressure was offset by strength in Meta, but overall sentiment remained cautious due to rising oil prices and geopolitical tensions. Amid this backdrop, value stocks present an appealing opportunity.
When evaluating value stocks, one of the most effective valuation metrics is the Price to Cash Flow (P/CF) ratio. This metric measures the market price of a stock relative to the cash flow the company generates on a per-share basis. A lower P/CF ratio indicates that the stock is trading at a better value, offering strong cash generation potential relative to its price. Here are four companies — Harmony Biosciences Holdings, Inc., Universal Health Services, Inc., Concentrix Corp. and Global Payments Inc. — that boast a low P/CF ratio.
Price to Cash Flow Reveals Financial Health
Questions may arise as to why we are considering the P/CF valuation metric when the most widely used metric is Price/Earnings (or P/E). Well, what makes P/CF stand out is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, reflecting a company's financial health.
Analysts caution that a company's earnings are subject to accounting estimates and management manipulation. However, cash flow is reliable. It is net cash flow that reveals how much money a company is actually generating and how effectively management is putting the same to use.
A positive cash flow indicates an increase in the company's liquid assets. This gives the company the means to settle debt, shell out for its expenses, reinvest in its business, endure downturns and finally pay back its shareholders. Then again, a negative cash flow implies a decline in the company's liquidity, which lowers its flexibility to support these moves.
What's the Best Value Investing Strategy?
An investment decision solely based on the P/CF metric may not fetch the desired results. To identify stocks that are trading at a discount, you should expand your search criteria and consider the price-to-book ratio, price-to-earnings ratio and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of A or B to your search criteria should lead to even better results, as these eliminate the chance of falling into a value trap.
Here are four of the nine value stocks that qualified the screening:
Harmony Biosciences, a pharmaceutical company, sports a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 7.2%, on average. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Harmony Biosciences' current financial-year sales and earnings per share (EPS) indicates growth of 21.4% and 25.9%, respectively, from the year-ago period. HRMY has a Value Score of A. Shares of HRMY have lost 4.9% in the past year.
Universal Health Services, which through its subsidiaries owns and operates acute care hospitals and outpatient and behavioral health care facilities, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 15.2%, on average.
The Zacks Consensus Estimate for Universal Health Services' current financial-year sales and EPS calls for growth of 9.7% and 31.3%, respectively, from the year-ago period. UHS has a Value Score of A. Shares of UHS have risen 6.1% in the past year.
Concentrix Corporation, a global technology and services leader providing customer experience solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 1%, on average.
The Zacks Consensus Estimate for Concentrix's current financial-year sales and EPS suggests growth of 2.9% and 4.8%, respectively, from the year-ago period. CNXC has a Value Score of A. Shares of CNXC have plunged 26.1% in the past year.
Global Payments, a leading worldwide provider of payment technology and software solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 1.9%, on average.
The Zacks Consensus Estimate for Global Payments' current financial-year sales and EPS implies growth of 1.8% and 5.8%, respectively, from the year-ago period. GPN has a Value Score of A. Shares of GPN have plunged 36.8% in the past year.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and backtest them first before taking the investment plunge.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2826332/4-value-stocks-to-consider-as-tech-volatility-weighs-on-wall-street
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.